Trials advance as platform power shifts
The cure wire stayed active today: 21,252 active trials, 104 new signals, and 49 new research items in the last 24 hours. United Therapeutics reached full enrollment in TETON-PPF for inhaled treprostinil in progressive pulmonary fibrosis, while argenx and Zai Lab reported positive topline Phase 3 results for efgartigimod in autoimmune myositis. Around the market, the signal is less about a single drug than about control points: code hosting, defaults, infrastructure, and the gap between prestige models and what developers actually choose. The race to cure disease is still being shaped by the race to own the rails beneath it. The window is still open.
United Therapeutics announced full enrollment of the Phase 3 TETON-PPF study of inhaled treprostinil for progressive pulmonary fibrosis, and argenx with Zai Lab reported positive topline Phase 3 ALKIVIA results for efgartigimod in autoimmune myositis.
These readouts matter because late-stage progress can turn biologic insight into usable treatments for diseases with high unmet need, while the platform shifts around AI and infrastructure determine who controls the tools, data, and capital that speed or slow discovery.
Watch for full trial data, regulatory follow-through, and whether platform defaults and infrastructure bets continue to concentrate leverage before the next wave of clinical readouts arrives.